Still, the proposed role for GRN across FTLD in conjunction with an appearance of asymmetric cortical atrophy specific to the mutation carriers has provided a strong argument to determine regulatory mechanisms, including epigenetic mechanisms, influencing GRN expression [101, 102]. The gene discussed is GRN; the disease is Cerebral cortical atrophy.